|
Age at initial diagnosis (years), median (range)
|
51 (28–77)
|
|
FIGO stage at diagnosis (%)a
|
|
Early (I + II)
|
13 (44.8%)
|
|
Advanced (III + IV)
|
16 (55.2%)
|
|
Platinum resistant recurrence (%)
|
12 (34.3%)
|
|
Serum CA-125 level at recurrence (U/mL), median (range)
|
35.1 (3.90–829.2)
|
|
Serum CA-199 level at recurrence (U/mL), median (range)
|
12.01 (0.5–1000)
|
|
Number of recurrent tumor lesions
|
|
Single (%)
|
15 (42.9%)
|
|
Multiple (%)
|
20 (57.1%)
|
|
Type of treatment
|
|
Secondary cytoreduction surgery + chemotherapy
|
27 (77.1%)
|
|
Chemotherapy
|
8 (22.9%)
|
|
Follow up time (months), median (range)b
|
36.5 (7–155)
|
|
Disease status at last follow upb
|
|
Dead (%)
|
22 (64.7%)
|
|
Alive with disease (%)
|
12 (35.3%)
|
|
Progression-free survival (months), median (range)
|
13 (2–135)
|
|
Post-relapse survival (months), median (range)
|
17 (4–126)
|
